Causes and timing of mortality and morbidity among late presenters starting antiretroviral therapy in the REALITY trial

Causes and timing of mortality and morbidity among late presenters starting antiretroviral therapy in the REALITY trial

<p>Background: In sub-Saharan Africa, 20%-25% of people starting ART have severe immunosuppression; ~10% die within three months. In the recently-reported REALITY randomized trial, a broad enhanced anti-infection prophylaxis bundle reduced all-cause mortality versus cotrimoxazole alone; here,...

Bibliográfalaš dieđut
Váldodahkkit:	Post, F, Szubert, A, Prendergast, A, Johnston, V, Lyall, H, Fitzgerald, F, Musiime, V, Musoro, G, Chepkrorir, P, Agutu, C, Mallewa, J, Rajapakse, C, Wilkes, H, Hakim, J, Mugyenyi, P, Walker, A, Gibb, D, Pett, S, on behalf of the REALITY trial team
Materiálatiipa:	Journal article
Almmustuhtton:	Oxford University Press 2018

Geahča maid

Enhanced prophylaxis with antiretroviral therapy for advanced HIV in Africa
Dahkki: Hakim, J, et al.
Almmustuhtton: (2017)

Effect of ready-to-use supplementary food on mortality in severely immunocompromised HIV-infected individuals in Africa initiating antiretroviral therapy (REALITY): an open-label, parallel-group, randomised controlled trial
Dahkki: Mallewa, J, et al.
Almmustuhtton: (2018)

Pubertal development in HIV-infected African children on first-line antiretroviral therapy.
Dahkki: Szubert, A, et al.
Almmustuhtton: (2015)

Prevalence of lipodystrophy and metabolic abnormalities in HIV-infected African children after 3 years on first-line antiretroviral therapy.
Dahkki: Bwakura-Dangarembizi, M, et al.
Almmustuhtton: (2015)

Virologic response to first-line efavirenz- or nevirapine-based antiretroviral therapy in HIV-infected African children
Dahkki: Kekitiinwa, A, et al.
Almmustuhtton: (2017)

Single-dose nevirapine exposure does not affect response to antiretroviral therapy in HIV-infected African children aged below 3 years.
Dahkki: Musoke, P, et al.
Almmustuhtton: (2015)

The cost-effectiveness of prophylaxis strategies for individuals with advanced HIV starting treatment in Africa
Dahkki: Walker, SM, et al.
Almmustuhtton: (2020)

Tuberculosis incidence is high in HIV-infected African children but is reduced by co-trimoxazole and time on antiretroviral therapy.
Dahkki: Crook, A, et al.
Almmustuhtton: (2016)

Raltegravir-intensified initial antiretroviral therapy in advanced HIV disease in Africa: A randomised controlled trial
Dahkki: Kityo, C, et al.
Almmustuhtton: (2018)

Baseline inflammatory biomarkers identify subgroups of HIV-infected African children with differing responses to antiretroviral therapy
Dahkki: Prendergast, A, et al.
Almmustuhtton: (2016)

Predicting patterns of long-term CD4 reconstitution in HIV-infected children starting antiretroviral therapy in sub-Saharan Africa: a cohort-based modelling study.
Dahkki: Picat, M, et al.
Almmustuhtton: (2013)

Marginal structural models for repeated measures where intercept and slope are correlated: an application exploring the benefit of nutritional supplements on weight gain in HIV-infected children initiating antiretroviral therapy
Dahkki: Farmer, R, et al.
Almmustuhtton: (2020)

Virological response and resistance among HIV-infected children receiving long-term antiretroviral therapy without virological monitoring in Uganda and Zimbabwe: Observational analyses within the randomised ARROW trial
Dahkki: Szubert, A, et al.
Almmustuhtton: (2017)

Mortality in the year following antiretroviral therapy initiation in HIV-infected adults and children in Uganda and Zimbabwe.
Dahkki: Walker, A, et al.
Almmustuhtton: (2012)

Benefits of enhanced infection prophylaxis at antiretroviral therapy initiation by cryptococcal antigen status
Dahkki: Pett, SL, et al.
Almmustuhtton: (2020)

Highly active antiretroviral therapy reduces mortality and morbidity in patients with AIDS in Sungai Buloh Hospital
Dahkki: Mat Shah, R., et al.
Almmustuhtton: (2012)

Monitoring of highly active antiretroviral therapy in HIV infection.
Dahkki: Walker, A, et al.
Almmustuhtton: (2011)

Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): a 5-year open-label randomised factorial trial.
Dahkki: Kekitiinwa, A, et al.
Almmustuhtton: (2013)

Approaches towards avoiding lifelong antiretroviral therapy in paediatric HIV infection.
Dahkki: Goulder, P, et al.
Almmustuhtton: (2011)

Outcomes for human immunodeficiency virus-1-infected infants in the United kingdom and Republic of Ireland in the era of effective antiretroviral therapy.
Dahkki: Doerholt, K, et al.
Almmustuhtton: (2006)

Absence of antiretroviral therapy and other risk factors for morbidity and mortality in Malaysian compulsory drug detention and rehabilitation centers
Dahkki: Fu, J.J., et al.
Almmustuhtton: (2012)

Impact of efavirenz, ritonavir-boosted lopinavir and nevirapine based antiretroviral regimens on the pharmacokinetics of lumefantrine and safety of artemether-lumefantrine in falciparum-negative HIV-infected Malawian adults stabilized on antiretroviral therapy
Dahkki: Banda, CG, et al.
Almmustuhtton: (2018)

Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort.
Dahkki: Walker, A, et al.
Almmustuhtton: (2010)

Underdosing of antiretrovirals in UK and Irish children with HIV as an example of problems in prescribing medicines to children, 1997-2005: cohort study.
Dahkki: Menson, E, et al.
Almmustuhtton: (2006)

Improved adherence to antiretroviral therapy observed among HIV-infected children whose caregivers had positive beliefs in medicine in Sub-Saharan Africa
Dahkki: Abongomera, G, et al.
Almmustuhtton: (2016)

Beyond clinical trials: Cross-sectional associations of combination antiretroviral therapy with reports of multiple symptoms and non-adherence among adolescents in South Africa
Dahkki: Natukunda, H, et al.
Almmustuhtton: (2017)

John Dobson : architect & landscape gardener /
Dahkki: 387860 Wilkes, Lyall
Almmustuhtton: (1980)

Absence of antiretroviral therapy and other risk factors for morbidity and mortality in Malaysian compulsory drug detention and rehabilitation centers
Dahkki: Zhou, Dongsheng, et al.
Almmustuhtton: (2012)

Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy.
Dahkki: Reid, A, et al.
Almmustuhtton: (2008)

Pharmacokinetics and safety profile of artesunate-amodiaquine co-administered with antiretroviral therapy in malaria uninfected HIV-positive Malawian adults
Dahkki: Banda, C, et al.
Almmustuhtton: (2018)

Biomarkers of mortality in adults and adolescents with advanced HIV in sub-Saharan Africa
Dahkki: Riitho, V, et al.
Almmustuhtton: (2024)

Pharmacokinetics of piperaquine and safety profile of dihydroartemisinin-piperaquine co-administered with antiretroviral therapy in malaria-uninfected HIV-positive Malawian adults
Dahkki: Banda, C, et al.
Almmustuhtton: (2018)

Anthropometric measurements and lipid profiles to detect early lipodystrophy in antiretroviral therapy experienced HIV-infected children in the CHAPAS-3 trial.
Dahkki: Musiime, V, et al.
Almmustuhtton: (2014)

Plasma calprotectin as a biomarker of mortality at antiretroviral treatment initiation in advanced HIV – pilot study
Dahkki: Kamau, FW, et al.
Almmustuhtton: (2020)

Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretroviral therapy with baseline creatinine clearance of 30-49 vs ≥50 mL/min
Dahkki: Ross, LL, et al.
Almmustuhtton: (2019)

Inflammatory biomarkers in HIV-infected children hospitalized for severe malnutrition in Uganda and Zimbabwe
Dahkki: Prendergast, A, et al.
Almmustuhtton: (2019)

Virologic response to first-line efavirenz- or nevirapine-based anti-retroviral therapy in HIV-infected African children
Dahkki: Kekitiinwa, A, et al.
Almmustuhtton: (2017)

Determinants of survival without antiretroviral therapy after infancy in HIV-1-infected Zambian children in the CHAP Trial.
Dahkki: Walker, A, et al.
Almmustuhtton: (2006)

Affordable HIV drug-resistance testing for monitoring of antiretroviral therapy in sub-Saharan Africa.
Dahkki: Inzaule, S, et al.
Almmustuhtton: (2016)

When to start antiretroviral therapy in HIV-associated tuberculosis.
Dahkki: Török, M, et al.
Almmustuhtton: (2011)